Physostigmine and Breastfeeding

Summary of use during lactation

No information is available on the use of physostigmine during breastfeeding. It should be used during breastfeeding if it is essential to the mother’s health.

Drug levels in milk and infant serum

Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information in nursing mothers was not found as of the revision date. In animals, cholinergic drugs increase oxytocin release,[1] and physostigmine increases serum prolactin in humans.[2,3] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1. Clarke G, Fall C, Lincoln D, et al. Effects of cholinoceptor antagonists on the suckling-induced and experimentally evoked release of oxytocin. Br J Pharmacol 1978;63:519-27.566601
2. Risch S, Janowsky D, Siever L, et al. Cholinomimetic-induced co-release of prolactin and beta-endorphin in man. Psychopharmacol Bull 1982;18:21-5.6296908 PubMed
3. Risch S, Janowsky D, Siever L, et al. Correlated cholinomimetic-stimulated beta-endorphin and prolactin release in humans. Peptides 1982;3:319-22.6289276 PubMed